COVID-19 vaccines should not be affected by SARS-CoV-2 mutations, researchers say
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
List view / Grid view
News
Nobel Prize in Chemistry awarded to scientists who discovered CRISPR-Cas9
Emmanuelle Charpentier and Jennifer Doudna have been given the 2020 Nobel Prize in Chemistry for their discovery and development of CRISPR-Cas9 genome editing.
High doses of favipiravir combat SARS-CoV-2 in hamsters
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
Researchers suggest blocking factor D protein could combat SARS-CoV-2
A team has said that inhibiting the factor D protein could prevent SARS-CoV-2 from turning the immune system against healthy cells.
CRISPR used to eliminate cancers caused by fusion genes
Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
New class of inhibitors protect mice from neurodegeneration
So called "interface inhibitors" could be used to protect against neurodegeneration, researchers have said.
SARS-CoV-2-targeting antibodies persist for at least three months in COVID-19 patients
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
Single-nucleus transcriptomics reveals novel epilepsy targets
Study reveals which neurons are most affected by epilepsy, presenting novel targets for seizure drug discovery and development.
SARS-CoV-2 mechanism of infection revealed using cryo-electron microscopy
Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-750x500.jpg)
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-scaled-e1602154798857.jpg)
Researchers identify a potential remdesivir resistance mechanism in SARS-CoV-2
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
Researchers make steps towards a universal flu vaccine
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
Build-up in the lungs could be targeted by future severe COVID-19 treatments
Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.
NIH to support 85 highly innovative research projects
The US National Institutes of Health (NIH) will award a total of $251 million over five years to 85 high-risk, high-reward biomedical or behavioural research projects.
Scientists propose treating SARS-CoV-2 with sofosbuvir and remdesivir
Researchers have posited that SARS-CoV-2 could be combatted by sofosbuvir, in combination with other antivirals such as remdesivir.
Lead drug candidate identified as potential neuroblastoma treatment
Using hit-to-lead processes, researchers have discovered that KSP inhibitors prevent tumour growth and prolong survival in mice with neuroblastoma.
